Section 12
Investment Thesis
$22K self-funded to build the Function Health of treatment
TL;DR
This business needs $22K to start — not millions. We don't need investors because the model pays for itself within 8-10 months. After that, every dollar of profit gets reinvested into growth. Function Health reached a $2.5B valuation with 100K members paying $365/year — we offer everything they do PLUS treatment. By Year 5, we target $40M revenue and $8.8M profit with 100% founder ownership. If we ever raise money, it's a strategic choice (own pharmacy to cut costs), not a survival need.
Initial Capital
$22K
Break-even
Month 8-10
Year 5 Revenue
$40M
Year 5 Profit
$8.8M
BioForge is a self-funded full longevity platform for men, built on the same lean model Medvi used to go from $20K to $1.8B annualized. No VC, no dilution, no burn rate pressure. $22K in, profitable by month 8-10, and every dollar of profit reinvested into growth. The key comparable: Function Health reached a $2.5B valuation with 100K members paying $365/year for blood tests — but they CANNOT treat what they find. BioForge offers testing AND treatment in one platform. Blood work with 100+ biomarkers ($365/yr, 75-85% margin) is the gateway product. Then AI app ($29/mo), peptide therapy ($149-499/mo), and premium longevity plans ($5-50K/yr). Why this works without external capital: 1. Medvi proved $20K is enough to launch — telehealth infrastructure is plug-and-play 2. AI tools reduce operational cost by 90%+ vs. 2020 (one person can run this) 3. Quiz funnel achieves 70-80% completion, 40-60% lower CPA than traditional funnels 4. Blood work at $365/yr with 75-85% margins funds growth almost immediately 5. Men who train are high-LTV customers — they stack products, stay on protocols, refer friends 6. Cash-pay model means immediate revenue (no insurance delays) 7. Dubai 0% tax means every dollar of profit compounds faster Optional future capital ($2-3M at $5-10M+ revenue) ONLY if choosing to vertically integrate: - Own 503B pharmacy license drops COGS from 25% to 10%, margin jumps from 45% to 72% - This is a strategic choice, not a survival need — the business is already profitable - Alternative: stay lean and extract $5-10M+ annual profit like Medvi
Funding Requirements
Amount
$22,000
Instrument
Self-funded (founder capital)
Valuation Cap
N/A — no external investors at launch
Runway
8-10 months to break-even, then self-sustaining from revenue
Use of Funds
Return Scenarios (5-Year)
Y5 Revenue
$20M
Y5 Net Profit
$3.5M
Implied Valuation
N/A — private cash-cow business
ROI on $500K
$3.5M/year profit on $22K invested. 159x cumulative return.
Slower growth, US only, no vertical integration. Still extremely profitable.
Y5 Revenue
$40M
Y5 Net Profit
$8.8M
Implied Valuation
$120M (3x revenue) if ever sold
ROI on $500K
$8.8M/year profit on $22K invested. 400x cumulative return.
Moderate growth, US + UAE, 10 peptides, reinvest profits into growth.
Y5 Revenue
$60M
Y5 Net Profit
$18M
Implied Valuation
$240M (4x revenue)
ROI on $500K
$18M/year profit. Raise $2-3M at Year 3 for own pharmacy — 72% gross margin.
Raise capital at $5-10M revenue for 503B pharmacy license. COGS drops from 25% to 10%. Multi-market.
Exit Strategy
Profitable Private Company (Default Path)
Following the Medvi/Gallagher model — remain private, extract profits, no exit needed. At $40M revenue and 22% net margin, that's $8.8M/year in profit with 100% founder ownership. No investors to answer to.
Strategic Acquisition (If the Price is Right)
At $40M+ revenue with a strong men's brand, acquisition by Hims, Ro, GoodRx, or a PE firm becomes attractive. Only sell if the offer is life-changing (3-5x revenue = $120-200M).
Vertical Integration & Scale
Raise $2-3M at $5-10M revenue to acquire/build a 503B compounding pharmacy. COGS drops from 25% to 10%, margin jumps dramatically. This is a growth accelerator, not a survival need.
Private Equity Buyout
PE firms love profitable DTC health brands with recurring revenue. At 22% net margin, BioForge is a PE dream. Sell 60-80% while retaining operational control.
Milestone-Based Funding
Company Formation
Dubai free zone LLC, US entity, telehealth partner agreement
$7KProduct Launch
Website live, 3 peptides (BPC-157, CJC-1295+Ipamorelin, semaglutide), first paid ads
$10K500 Customers
Product-market fit validated with male fitness audience
$5KBreak-even (Month 8-10)
Profitable on monthly basis, reinvesting into growth. ~1,000 customers.
$600K Revenue / Year 1
3,000 customers, full peptide catalog, all growth self-funded
$3M Revenue / Year 2
8,000 customers, first hire, UAE market prep
$10M Revenue / Year 3
15,000 customers. Decision point: raise capital for own pharmacy or stay lean.
$40M Revenue / Year 5
24,000 subscribers, 22% net margin, $8.8M annual profit
Why Now
- 1Regulatory window: FDA peptide reclassification creates time-limited first-mover advantage
- 2Proven model: Medvi went from $20K to $1.8B annualized — the infrastructure works
- 3$22K is all it takes: telehealth-as-a-service + AI tools = near-zero startup cost
- 4Men who train are the best customers: high LTV, protocol adherence, word-of-mouth
- 5Dubai 0% tax: every dollar of profit compounds faster than US-based competitors
- 6No investors needed: profitable by month 8-10, then growth funds itself
- 7Optional vertical integration at $10M+: own pharmacy drops COGS from 25% to 10%